Loading
Hamlet BioPharma AB Stock: price and insider trades · Sweden
No insider purchase over the last 90 days. The latest was filed 29 Mar 2026.
Hamlet BioPharma AB: what insiders have been doing
Every trade that managers of Hamlet BioPharma AB disclose to Finansinspektionen is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 18 October 2026, brought 7 filings signed by 2 insiders.
The record shows 1 purchase on the open market worth €16k, made by 1 insider, against 6 sales worth €56k by 1 insider. On balance, insiders were net sellers of €40k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a purchase of €16k from Marianne Catharina Svanborg, disclosed on 29 March 2026, or 0.014% of market capitalisation. The buyers include 1 board member.
Across the 890 companies tracked on its exchange, the median is 7 filings; at 7 filings, this issuer sits right on that mark. Looking back to 2026, when coverage begins, insiders filed 1 purchase and 6 sales.
The most recent open-market purchase was published on 29 March 2026, 203 days ago. The median gap between a trade and its publication by Finansinspektionen is 3 days. Under the Market Abuse Regulation, managers have three business days to notify their trades. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Insider Decl.
7
Thresholds
n/a
Buy Volume
€16,127
1 ops. · all time
Sell Volume
€55,806
6 ops. · all time
Who traded when
BuySaleHenrik Sundin6 sales
Marianne Catharina Svanborg1 buy
Since the insiders bought
- -24.6%Entry SEK 7.80 · Close 15 Oct 2026 SEK 5.88
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2026FY ended June 2026 · cache
SEK 6.07
Analyst consensus
Income statement
EBITDA-SEK 45.6M
Net income-SEK 55.6M0.0% margin
Valuation
P/Book57.3x
Beta0.27
Balance sheet & cash
Market capSEK 1.2B
Free Cash Flow-SEK 44.6M
Profitability & ownership
ROE-198.3%
ROA-97.2%
Last declaration on 25 May 2026
Declarations7 total
10,000 shares@ SEK 7.580.0060% mcap12.4% of flowAktieISIN SE0015661152FI:csv-8b1223654d29b5466fcb
20,000 shares@ SEK 7.650.012% mcap25.1% of flowAktieISIN SE0015661152FI:csv-69bdd949cde8b5d12cf1
10,000 shares@ SEK 7.610.0060% mcap12.5% of flowAktieISIN SE0015661152FI:csv-74c6872ba2c9fa3745f0
10,000 shares@ SEK 7.630.0061% mcap12.5% of flowAktieISIN SE0015661152FI:csv-628a2bf8649801cf1f97
10,000 shares@ SEK 7.4912.4% of flowAktieISIN SE0015661152FI:A003Z114-1
20,000 shares@ SEK 7.7025.2% of flowAktieISIN SE0015661152FI:A003Z083-1
25,000 shares@ SEK 6.980.014% mcap100.0% of flowAktieISIN SE0015661152FI:A003X421-1
Canonical exit: 24 Jun 2026 (T+90)
7 of 7 declarations
About Hamlet BioPharma AB
Hamlet BioPharma AB is a company focused on developing innovative cancer treatments. It is listed on the XSTO market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
